Keywords: BM; brain metastasis; AE; adverse event; CI; confidence interval; CTLA4; cytotoxic T-lymphocyte antigen-4; CT; computed-tomography; GPA; Graded Prognostic Assessment score; IORR; intracerebral objective response rate; IQR; interquartile range; NSCLC; nonâ
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: IL1β; Pentose phosphate pathway; PDL1; Early-stage; NSCLC; Prognosis; Inflammation;
Keywords: APC; antigen presenting cell; APOBEC; apolipoprotein B mRNA editing enzyme catalytic polypeptide-like; BRCA1/2; breast cancer 1/2; BCSS; breast cancer specific survival; B2M; β-2-microglobulin; CAF; cancer associated fibroblast; CCL; chemokine ligand; CD
Keywords: GBM; Glioblastoma multiforme; CARs; chimeric antigen receptors; PDL1; programmed death ligand 1; IDH1; isocitrate dehydrogenase 1; PMN; polymorphonuclear; TAMs; tumor associated macrophages; HLA; human leucocyte antigen; FLT3L; Fms-like tyrosine kinase 3
Pseudoprogression of CNS metastatic disease of alveolar soft part sarcoma during anti-PDL1 treatment
Keywords: Pseudoprogression; PDL1; Alveolar soft part sarcoma;
The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression
Keywords: Herpes virus entry mediator; Non small cell lung cancer; PDL1;
Emerging microRNAs in cancer diagnosis, progression, and immune surveillance
Keywords: Cancer immunity; miR-21; miR-375; oncomiR; Prognostic biomarker; RAS pathway; AKT; serine/threonine-protein kinase; CIP2A; cancerous inhibitor of PP2A; ERK; extracellular-signal-regulated kinase; FFPE; formalin-fixed, paraffin-embedded; HNC; head and neck
Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas
Keywords: Vulvar melanoma; Survival; PDL1; CD8; FoxP3; Immunohistochemistry;
Novel minor HLA DR associated antigens in type 1 diabetes
Keywords: IM; Inflammatory myositis; MLH1; MutL homolog; MTIF3; Mitochondrial translational initiation factor 3; NAPPA Array; Nucleic acid programmable protein arrays; NUP50; Nucleoporin 50; PD-1; Programmed cell death protein 1; PDL1; Programmed cell death 1 ligan
ReviewImmunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges
Keywords: Non-small-cell lung cancer; Immune checkpoint inhibitor; Pembrolizumab; Nivolumab; Atezolizumab; PDL1; PD1;
Hematologic neoplasms: Dendritic cells vaccines in motion
Keywords: DCs; dendritic cells; TAA; tumor-associated antigens; APC; antigen presenting cells; mDCs; myeloid dendritic cells; pDCs; plasmacytoid dendritic cells; HLA; human leukocyte antigen; Ag Antigens; abs antibodies; PBMCs; peripheral blood mononuclear cells; G
Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma
Keywords: PDL1; B7-H1; Urothelial carcinoma; Immunotherapy; Neoadjuvant chemotherapy;
Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas
Keywords: PDL1; Hodgkin lymphoma; B-cell lymphoma; Immunohistochemistry; Diagnostic marker;
Serum amyloid A induces mitogenic signals in regulatory T cells via monocyte activation
Keywords: CD36; thrombospondin receptor; FPR2; formyl peptide receptor 2; HC; healthy control; HVEM; herpesvirus entry mediator; IL1RA; IL-1 receptor antagonist; PDL1; program death ligand 1; PDL2; program death ligand 2; RAGE; receptor of advanced glycation end-pr
Therapeutic polyclonal human CD8Â + CD25Â + Fox3Â + TNFR2Â + PD-L1Â + regulatory cells induced ex-vivo
Keywords: Polyclonal CD8Â + regulatory T cells; Cell-based immunotherapy; IL-2; TGF-beta; TNFR2; PDL1;